Диссертация (1146694), страница 22
Текст из файла (страница 22)
Veksler, A. Minajeva, A. Kaasik, P. Mateo et all. //Circulation Research. – 1999. – V. 85. – №. 1. – P. 68 – 76.98.Diaz R. Metabolic modulation of acute myocardial infarction: the ECLAGlucose Insulin Potassium Pilot Trial / R. Diaz, E.
A. Paolasso, L. S. Piegas, C. D.143Tajer, M. G. Moreno, R. Corvalan, J. E. Isea, G. Romero // Circulation. – 1998. –V. 98. – № 21. – P. 2227 – 2234.99.Di Stasi D. Early modifications of fatty acid composition in plasmaphospholipids, platelets and mononucleates of healthy volunteers after low dosesof n-3 polyunsaturated fatty acids / D.
Di Stasi, R. Bernasconi, R. Marchioli, R. M.Marfisi, G. Rossi, G. Tognoni, M. T. Tacconi // Eurean Journal of ClinicalPharmacology. – 2004. – V. 60. – № 3. – Р. 183 – 190.100. Dycka J. R. B. Metabolic signals of arrhythmia / J. R. B. Dycka, P. E. Light// Heart and Metabolism. – 2006. – № 33. – Р. 5 – 8.101.
ESC Guidelines for the diagnosis and treatment of acute and chronic heartfailure 2012. The Task Force for the Diagnosis and Treatment of Acute andChronic Heart Failure 2012 of the European Society of Cardiology. Developed incollaboration with the Heart Failure Association (HFA) of the ESC // EuropeanHeart Journal. – 2012. – V. 33. – P. 1787–1847.102.
Fath–Ordoubadi F. Glucose–Insulin–Potassium therapy for treatment ofacute myocardial infarction: an overview of randomized placebo controlled trials /F. Fath–Ordoubadi, K. Beatt // Circulation. – 1997. – V. 96. – № 4. – P.1152 –1156.103. Firuzi О. Effects of Omega-3 Polyunsaturated Fatty Acids on HeartFunction and Oxidative Stress Biomarkers in Pediatric Patients with DilatedCardiomyopathy / O. Firuzi, N.
Shakibazad, H. Amoozgar, M. Borzoee, S. Abtahi,G. Ajami, P. Ardi, R. Miri // International Cardiovascular Research Journal. –2013. – №7(1). – Р. 8 – 14.104. Gluck T. Marine omega-3 highly unsaturated fatty acids: From mechanismsto clinical implications in heart failure and arrhythmias / T. Gluck, P. Alter //Vascular Pharmacology. – 2016. – № 82. – P. 11 – 19.105. Grigioni F.
Distance between patients subjective perceptions and objectivelyevaluated disease severity in chronic heart failure / F. Grigioni, S. Carigi, S.Grandi, L. Potena, F. Coccolo, L. Bacchi-Reggiani, G. Magnani, E. Tossani, A. C.144Musuraca, C. Magelli, A. Branzi // Psychotherapy and Psychosomatics. – 2003. –V. 72. – № 3. – P. 166 – 170.106. Goodfellow J. Dietary supplementation with marine omega-3 fatty acidsimprovesystemiclargearteryendothelialfunctioninsubjectswithhypercholesterolemia / J. Goodfellow, M. F. Bellamy, M.
W. Ramsey // Journal ofthe American College of Cardiology. – 2000. – V. 35. – № 2. – Р. 265 – 270.107. Gosse P. Echocardiographic definition of left ventricular hypertrophy in thehypertensive: which method of indexation of left ventricular mass? / P. Gosse, V.Jullien, P. Jarnier, P.
Lemetayer, J. Clementy // Journal of Human Hypertension. –1999. – V. 13. – P. 505 – 509.108. GISSI-Prevenzione Investigator. Dietar y simpplementation with ω-3polyunsaturated fatty acids and vitamin E in 11, 324 patients with myocardialinfarction: result of the GISSI Prevenzione trial // Lancet. – 1999. – V.354. – P.447 – 455.109. GISSI-HF Investigators.
Effect of n-3 polyunsaturated fatty acids in patientswith chronic heart failure (the GISSI-HF trial): a randomised, dou ble-blind,placebo-controlled trial // Lancet. – 2008. – № 372. – Р. 1223–1230.110. Harris W.S. Blood omega-3 and trans fatty acids in middle-aged acutecoronary syndrome patients / W. S.Harris, K.
J. Reid, S. A. Sands, J. A. Spertus //American Journal of Cardiology. – 2007. – V. 99. – № 2. – Р. 154 – 158.111. Harris W. S. Biological variability of blood omega-3 biomarkers / W. S.Harris, R. M. Thomas // Clinical Biochemistry – 2010. – № 43. – P. 338 – 340.112. Heller A. Lipid mediators ininflammatory disorders / A. Heller, T.
Koch, J.Schmeck, K. van Ackern // Drugs. – 1998. – V. 55. – № 4. – Р. 487 – 496.113. Hibbeln J. R. Healthy intakes of n-3 and n-6 fatty acids: estimationsconsidering worldwide diversity / J. R. Hibbeln, L. R. Nieminen, T. L. Blasbalg, J.A. Riggs, W. E. Lands // American Journal of Clinical Nutrition. – 2006. – V.
83. –№ 6. – Р. 1483 –1493.114. Hoogeveen E.K. No effect of n-3 fatty acids supplementation on NTproBNP after myocardial infarction: The alpha omega trial / E.K. Hoogeveen, J.M.145Geleijnse, D. Kromhout, P. Van’T Sant, E.F. Gemen, R. Kusters, E.J. Giltay //European Journal of Preventive Cardiology. – 2015. – № 22. – P. 648 – 655.115. Ingwall J. S. Energy metabolism in heart failure and remodeling / J. S.Ingwall // Cardiovascular Research. – 2009. – V. 81. – № 3. – Р. 412 – 419.116. Kang J. X. Prevention of fatal cardiac arrhythmias by polyunsaturated fattyacids / J. X.
Kang, A. Leaf // American Journal of Clinical Nutrition. – 2000. – V.71. – № 1. – P. 202-207.117. Kannel W. B. The Epidemiology of heart failure / W. B. Kannel, A. J.Belangeer // American Heart Journal. – 1991. – V. 121. – P. 951 – 957.118. Kar S. Role of omega-3 fatty acids in the prevention of atrial fibrillation / S.Kar // Reviews in Cardiovascular Medicine. – 2013. – V. 14. – P. 82 – 91.119.
Kenchaiah S. Obesity and the risk of heart / S. Kenchaiah, J. Evans, D. Levyet al. // The New England Journal of Medicine. – 2002. – V. 347. – № 5. – Р. 358 –359.120. Kohashi K. Effects of eicosapentaenoic acid on the levels of inflammatorymarkers, cardiac function and long-term prognosis in chronic heart failure patientswith dyslipidemia / K. Kohashi, A. Nakagomi, Y. Saiki, T. Morisawa, M.
Kosugi,Y.Kusama,H.Atarashi,W.Shimizu//Journalof Atherosclerosis and Thrombosis. – 2014. – № 21. – Р. 712 – 729.121. KojuriJ.Effectofomega-3onbrainnatriureticpeptideandechocardiographic findings in heart failure: Double-blind placebo-controlledrandomized trial / J. Kojuri, M.A. Ostovan, G.R. Rezaian, P.A. Dialameh, N.Zamiri, M.B. Sharifkazemi, M. Jannati //Journal of Cardiovascular DiseaseResearch. – 2013.
– № 4. – Р. 20 – 24.122. La Rovere M.T. The autonomic nervous system and cardiovascular disease:Role of n-3 PUFAs / M.T. La Rovere, J.H. Christensen // Vascular Pharmacology.– 2015. – № 71. – Р. 1 – 10.123. Lavie С. J. Omega-3 Polyunsaturated Fatty Acids and CardiovascularDiseases / C. J. Lavie, R. V. Milani, M. R. Mehra, H. O. Ventura // Journal of theAmerican College of Cardiology. – 2009. – V. 54. – № 7. – Р. 585 – 594.146124. Leaf A.
Cardiovascular effects of n-3 fatty acids / A. Leaf, P. C. Weber //New England Journal of Medicine – 1988. – V. 318. – № 9. – P. 549 – 557.125. London B. Omega-3 fatty acids and cardiac arrhythmias: prior studies andrecommendations for future research: a report from the National Heart, Lung, andBlood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and theirRole in Cardiac Arrhythmogenesis Workshop / B. London, C.
Albert, M. E.Anderson, W. R. Giles et al. // Circulation. – 2007. – V.116. – № 10. – P. 320 –335.126. Lopaschuk G. D. Myocardial Fatty Acid Metabolism in Health and Disease/ G. D. Lopaschuk, J. R. Ussher, C. D. L. Folmes, J. S. Jaswal, W. C. Stanley //Physiological Reviews. – 2010. – V. 90.
– № 2. – Р. 207 – 258.127. Lee L. Metabolic manipulation in ischaemic heart disease, a novel approachto treatment / L. Lee, J. Horowitz, M. Frenneaux // European Heart Journal. –2004. – № 25. – Р. 634 – 641.128. Lee J. H. Omega-3 fatty acids for cardioprotection / J. H. Lee, J. H.O´Keefe, C. J. Lavie, R. Marchioli, W. S. Harris // Mayo Clinic Proceedings. –2008. – V. 83. – № 3. – Р. 324 – 332.129. Lucas J. K. Glucose–insulin–potassium infusion enhances myocardial wallmotion in patients with chronic ischemic heart failure / L.
J. Klein, L. M. C. vanCampen, T. H. Marwick // Heart and Metabolism. – 2005. – № 27. – Р.16 – 20.130. Мacchia A. For the GISSI – Prevenzione Investigator. Left ventricularsystolic disfunction, total mortality, and sudden death in parients with myocardialinfarction treated with ω – 3 – polyunsaturated fatty acids / A. Мacchia, G.Levantesi, M. G. Franzosi et al. // European Journal of Heart Failure – 2005.
– V.7. – P. 904 – 909.131. Мacchia A. For the GISSI – Prevenzione Investigator. Left ventricularsystolic disfunction, total mortality, and sudden death in parients with myocardialinfarction treated with ω – 3 – polyunsaturated fatty acids / A. Мacchia, G.Levantesi, M. G. Franzosi et al. // European Journal of Heart Failury – 2005. – V.7. – P. 904 – 909.147132.
Мacchia A. The rationale and design of the FOR omega ART Trial: Arandomized, double-blind, placebo-controlled, independent study to test theefficacy of omega-3 PUFA for the maintenance of normal sinus rhythm withprevious atrial fibrillation / A. Мacchia, S. Varini, H.Grancelli et al./ AmericanHeart Journal. – 2009. – V. 157. – №.3.
– P.423 – 427.133. Maggioni A. P. EURObservational Research Programme: regionaldifferences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HFPilot) / A. P. Maggioni, G. Filippatos, O. Chioncel, M. C. Leiro, J. Drozdz et al. //European Heart Journal.
– 2013. – V. 15. – P. 808–817.134. Marchioli R. Antiarrhythmic mechanisms of n-3-PUFA and the results ofthe GISSI-Prevenzione trial / R. Marchioli, G. Levantesi, A. Macchia, A. P.Maggioni, R. M. Marfisi, M. G. Silletta, L. Tavazzi, G.Tognoni, F. Valagussa;GISSI-Prevenzione Investigators // The Journal of Membrane Biology. – 2005. –V. 206. – № 2. – Р.117 – 128.135. Martino A. Omega 3 and atrial fibrillation: Where are we? / A. Martino, L.Pezzi, R. Magnano, E. Salustri, M.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
